ArticleCancer diagnosis & prognosis
The Prognostic Role of Inflammation on Hepatocellular Carcinoma.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Advanced hepatocellular carcinoma has dismal prognosis. The choice of optimal therapy for each patient is not characterized well. There is a growing need to describe the relation of predictive and prognostic factors with survival. In this study, we aimed to examine the impact of clinical factors and inflammatory markers on the prognosis. Patients and Methods: A total of 125 patients who were diagnosed between January 2011-April 2018 were enrolled retrospectively. Patients' demographics, performance status, tumoral characteristics and inflammation-based prognostic scores (neutrophil/lymphocyte ratio (NLR), prognostic nutritional index (PNI), aspartate aminotransferase/platelet count ratio (APRI)) were recorded. Univariate and multivariate analyses were performed to determine the prognostic factors for survival. Results: Median age of patients was 64 (range=22-85) with male dominancy ( Conclusion: Inflammation based scores, NLR and APRI were found to be associated with worse mOS. Larger tumor size, older age and ECOG PS were found to be independent prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.